To develop a method for mass-producing cancer-fighting immune cells from a single stem cell.
Key Findings:
One stem cell can generate up to ~14 million NK cells or ~7.6 million CAR-engineered NK cells.
A single cord blood unit could supply thousands of therapeutic doses.
The method reduces viral vector requirements for genetic engineering by up to ~600,000-fold.
Interpretation:
The new approach addresses long-standing bottlenecks in cell therapy manufacturing, improving yield and consistency while lowering costs.
Limitations:
The study primarily focuses on mouse models, necessitating further validation in human trials.
Conclusion:
The engineered CAR-NK cells effectively suppressed tumor growth and extended survival in leukemia models, retaining potency after cryopreservation, indicating potential for off-the-shelf immunotherapies.
